List of Excipients in Branded Drug VITAMIN D

Generic Drugs Containing VITAMIN D

Company	Ingredient	NDC	Excipient
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	ergocalciferol	23155-809	BUTYL ALCOHOL
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	ergocalciferol	23155-809	FD&C BLUE NO. 1
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	ergocalciferol	23155-809	FD&C YELLOW NO. 5
Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc	ergocalciferol	23155-809	GELATIN

What are the Most Frequently-Used Excipients in VITAMIN D?

# Of NDCs	Excipient
2	AMMONIA
4	BUTYL ALCOHOL
1	BUTYLATED HYDROXYANISOLE
4	D&C YELLOW NO. 10

Vitamin D Excipient Strategy and Commercial Opportunities in Pharmaceutical Formulation

Last updated: August 6, 2026

Vitamin D is a mature active pharmaceutical ingredient with limited composition-of-matter exclusivity and substantial opportunity in formulation, delivery, stability, and patient-convenience products. The strongest commercial positions are likely to come from differentiated oral dosage forms, high-dose adherence products, liquid and pediatric systems, combination products, and delivery technologies that improve dispersion or protect the active from degradation.

What vitamin D forms are used in pharmaceutical products?

Vitamin D is a family of secosteroid compounds rather than a single commercial ingredient. The main pharmaceutical forms are vitamin D2, vitamin D3, and active vitamin D analogues.

Active ingredient	Common name	Primary use	Formulation implications
Ergocalciferol	Vitamin D2	Prevention and treatment of vitamin D deficiency	Lipophilic, oxidation-sensitive, commonly formulated in capsules and oral liquids
Cholecalciferol	Vitamin D3	Deficiency treatment and supplementation	High potency, low dose loading, oil-based or solubilized delivery
Calcitriol	1,25-dihydroxyvitamin D3	Hypocalcemia, renal osteodystrophy, selected endocrine disorders	Potent active requiring tight dose uniformity and exposure control
Doxercalciferol	1-alpha-hydroxyvitamin D2	Secondary hyperparathyroidism in chronic kidney disease	Low-dose oral formulation, stability and dose precision are central
Paricalcitol	Vitamin D analogue	Secondary hyperparathyroidism	Oral and injectable formulation requirements differ materially

Vitamin D2 and D3 are nutritional or replacement actives. Calcitriol, doxercalciferol, and paricalcitol are pharmacologically active analogues with narrower therapeutic margins and more demanding dose-control requirements [1,2].

What excipient properties are required for vitamin D formulations?

The core excipient problem is that vitamin D is highly lipophilic, poorly water-soluble, and sensitive to light, oxygen, heat, and formulation conditions. Excipients must support solubilization, content uniformity, chemical stability, and consistent absorption.

The principal excipient functions are:

1. Oil-phase solubilization.
2. Protection from oxidation and light.
3. Homogeneous distribution of a low-dose active.
4. Improved dispersion in gastrointestinal fluids.
5. Taste masking in liquids and chewable products.
6. Physical stability during storage.
7. Manufacturing compatibility with softgels, hard capsules, tablets, and liquid systems.

Vitamin D3 has a molecular weight of approximately 384.6 g/mol and is practically insoluble in water. Its low daily dose creates a content-uniformity challenge, especially in tablets and multiparticulate systems. The active may be diluted in a premix before blending to reduce segregation risk.

Which excipients are commonly suitable for vitamin D?

Formulation function	Common excipient classes	Commercial rationale
Lipid vehicle	Medium-chain triglycerides, soybean oil, olive oil, corn oil	Supports dissolution and softgel or liquid filling
Surfactant	Polysorbates, sorbitan esters, poloxamers, lecithin	Improves wetting and dispersion
Cosolvent	Propylene glycol, polyethylene glycol, ethanol, glycerol	Supports liquid solubilization, subject to route and age restrictions
Antioxidant	Alpha-tocopherol, mixed tocopherols, ascorbyl palmitate	Reduces oxidative degradation
Solid carrier	Microcrystalline cellulose, lactose, mannitol, starches	Enables tablet compression and powder handling
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule and tablet integrity
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Accelerates tablet breakup
Coating system	Hypromellose, polyvinyl alcohol, polyethylene glycol	Protects the dosage form and improves swallowability
Taste masking	Sweeteners, flavors, ion-exchange resins, lipid barriers	Supports pediatric and chewable products
Chelating agent	Disodium EDTA, where appropriate	Reduces metal-catalyzed oxidation
Suspending agent	Xanthan gum, cellulose derivatives, carbomers	Controls settling in oral liquids

Excipient selection must be compatible with the intended regulatory category. An excipient used in a conventional oral product may not be suitable for an infant product, injectable formulation, or high-frequency chronic-use product. FDA’s Inactive Ingredient Database provides a reference point for prior route and dosage-form use, but it does not eliminate the need for product-specific safety and quality evaluation [3].

Which vitamin D formulation platforms offer the best commercial opportunities?

Oil-based softgels

Softgels remain the most established platform for vitamin D3 and D2. The active can be dissolved or dispersed in a lipid vehicle, with tocopherol or another antioxidant used to support stability.

Commercial advantages include:

• Low manufacturing complexity relative to advanced delivery systems.
• Good consumer familiarity.
• Compatibility with high-dose products.
• Efficient use of a small active dose.
• Broad contract-manufacturing availability.

The main limitations are gelatin-related market restrictions, leakage risk, oxygen exposure, and limited differentiation. Vegetarian softgels using pullulan or modified starch can command a premium but increase material and process costs.

Hard capsules and powder-filled systems

Powder-filled hard capsules allow combination products and controlled-release multiparticulates. They require a validated vitamin D premix because the active dose may be small relative to the total fill weight.

Suitable strategies include:

• Adsorption of vitamin D onto porous carriers.
• Spray-dried vitamin D premixes.
• Ordered mixing with carrier particles.
• Lipid-coated powders.
• Granulation with antioxidants and protective polymers.

This platform is attractive for vitamin D combined with calcium, magnesium, vitamin K, or renal-support ingredients. The principal technical risks are segregation, degradation during blending, and poor dissolution after storage.

Tablets and chewable tablets

Tablets offer lower unit costs and greater branding flexibility. Chewables provide a route to pediatric, geriatric, and adherence-focused products.

Commercial opportunities include:

• Sugar-free chewables.
• Low-calorie products.
• Fast-dispersing tablets.
• Orally disintegrating tablets.
• Combination bone-health products.
• High-dose intermittent tablets.

The excipient strategy must address taste, grittiness, dose uniformity, and vitamin D dispersion. Mannitol can provide a cooling mouthfeel in chewables, while microcrystalline cellulose and direct-compression excipients support manufacturing. Flavors and sweeteners must be selected with attention to stability and acceptable daily exposure.

Oral liquids and pediatric drops

Liquid vitamin D products have a strong use case in infants, children, older adults, and patients with swallowing difficulties. The product may be an oil solution, an emulsion, or a cosolvent-based system.

A preferred liquid strategy uses:

• A stable oil vehicle.
• An antioxidant system.
• Light-protective packaging.
• A calibrated dropper or oral syringe.
• Low-volume dosing.
• Preservative control where water is present.

Water-based emulsions can improve mouthfeel and dosing flexibility, but they introduce microbial, interfacial, and physical-stability risks. The development program must assess creaming, coalescence, particle-size drift, preservative performance, and dose delivery through the selected container closure.

Self-emulsifying and nanodispersed systems

Self-emulsifying drug-delivery systems can improve dispersion of vitamin D in gastrointestinal fluids. These systems usually combine an oil, surfactant, and cosurfactant that form a fine emulsion after dilution.

Potential commercial benefits include:

• Improved apparent solubility.
• More consistent dissolution.
• Reduced dependence on bile-mediated dispersion.
• Smaller dosage units.
• Differentiation from standard oil-filled products.

The risks include surfactant tolerability, capsule-shell compatibility, precipitation after dilution, and regulatory scrutiny of high excipient concentrations. A formulation that improves in vitro dispersion does not automatically establish clinically meaningful bioavailability improvement.

How should vitamin D excipients be selected for stability?

Vitamin D stability programs should focus on oxidation, photolysis, thermal degradation, and adsorption to packaging or processing surfaces.

Stability control strategy

Risk	Excipient or process response
Oxidation	Use tocopherols, reduce headspace oxygen, select low-peroxide excipients
Light degradation	Use opaque or amber packaging and light-protective coatings
Poor content uniformity	Manufacture a validated premix and control particle-size distribution
Adsorption	Screen contact materials and high-surface-area carriers
Liquid separation	Optimize emulsifier concentration, viscosity, and homogenization
Moisture-driven degradation	Use low-moisture excipients and high-barrier packaging
Dose drift	Use calibrated dispensing systems and in-use stability testing

Peroxide value is a critical quality attribute for lipid vehicles. Oxidized oils may accelerate active degradation. Excipient suppliers should provide batch-level peroxide and anisidine data where appropriate.

Packaging is part of the excipient strategy. High-barrier blister packs, opaque bottles, nitrogen flushing, desiccants, and unit-dose containers may provide greater commercial value than adding another stabilizer. Vitamin D products should be assessed in the final container closure under long-term, accelerated, photostability, and in-use conditions.

What FDA regulatory status applies to vitamin D products?

Vitamin D products fall into different regulatory categories depending on the active, claim, dose, dosage form, and labeling.

Prescription and over-the-counter drugs

Prescription vitamin D products, including certain ergocalciferol and vitamin D analogue products, are regulated as drugs. Their formulations, manufacturing processes, specifications, and inactive ingredients are evaluated through the drug approval pathway.

OTC and supplement status cannot be inferred solely from the presence of vitamin D. A product making disease-treatment claims may be regulated as a drug. Dietary supplements are subject to the Dietary Supplement Health and Education Act framework and must comply with applicable FDA manufacturing, labeling, and safety requirements [4].

Orange Book status

Vitamin D does not have one consolidated Orange Book listing. Orange Book status is product-specific and depends on the approved drug, sponsor, dosage form, strength, and NDA or ANDA record.

For a commercial assessment, the relevant questions are:

• Is the reference product listed in the Orange Book?
• Does it have an active patent listing?
• Is regulatory exclusivity still active?
• Are approved strengths and dosage forms available for generic development?
• Does the proposed product require an ANDA, 505(b)(2) application, or another pathway?

For mature vitamin D products, the principal barriers are usually formulation development, manufacturing reliability, quality documentation, and market access rather than basic active-ingredient exclusivity.

When does vitamin D lose exclusivity?

Vitamin D2 and D3 are long-established molecules with no meaningful new-molecule exclusivity for conventional products. Generic and multisource competition is therefore structurally high.

Potential exclusivity may still arise from:

• A novel delivery system.
• A new dosage form.
• A pediatric formulation.
• A combination product.
• A clinically supported bioavailability improvement.
• A method-of-use patent.
• A manufacturing process that produces a distinct pharmaceutical composition.
• Orphan or other product-specific regulatory designations.

Patent protection for a conventional vitamin D composition is generally vulnerable if the formulation uses known oils, antioxidants, binders, and capsule materials. Stronger claims require demonstrated technical effects, such as improved stability, reduced dose variability, enhanced exposure, or a clinically relevant dosing advantage.

What patent strategies can protect vitamin D formulations?

The strongest patent estate for vitamin D is likely to focus on formulation performance rather than the active ingredient itself.

Formulation patents

Potential claim areas include:

• Defined oil and antioxidant combinations.
• Specific surfactant-to-oil ratios.
• Nanodispersion particle-size ranges.
• Emulsion droplet-size distributions.
• Stabilized aqueous vitamin D systems.
• Low-peroxide lipid compositions.
• Moisture- or oxygen-barrier dosage forms.
• Taste-masked chewable formulations.
• Pediatric dose-delivery systems.

A formulation patent should connect the claimed composition to measurable performance. Useful evidence includes improved assay retention, reduced degradation products, improved dissolution, lower dose variability, or enhanced in-use stability.

Method-of-use patents

Method claims may target:

• Intermittent high-dose administration.
• Deficiency treatment in defined patient populations.
• Use with calcium or vitamin K.
• Renal disease or malabsorption populations.
• Pediatric or geriatric dosing.
• Administration through a specific delivery device.

Method-of-use claims face challenges from existing clinical practice and may have limited commercial value unless the product has a differentiated approved label.

Manufacturing and process patents

Manufacturing claims can address:

• Stabilized premix preparation.
• Low-oxygen filling.
• Controlled crystallization.
• Encapsulation of vitamin D in lipid or polymer matrices.
• Continuous blending for dose uniformity.
• Degradation-control processes.

Process patents are most valuable when they support a reproducible quality advantage or reduce cost at commercial scale. They are less useful if competitors can achieve the same product profile through a materially different process.

Is there biosimilar risk for vitamin D?

Vitamin D products do not create conventional biosimilar risk. Vitamin D2, D3, and their small-molecule analogues are chemically synthesized or isolated small molecules, not biologic medicines regulated under the biosimilar pathway.

Competitive risk comes from:

• Generic oral products.
• Authorized generics.
• Private-label supplements.
• Contract-manufactured products.
• Compounded products in limited circumstances.
• Alternative vitamin D analogues.
• Calcium and bone-health combination products.

The market is therefore more exposed to price erosion and retail substitution than to biologic interchangeability disputes.

Which commercial opportunities are most attractive?

Opportunity	Value proposition	Main barrier
High-dose adherence product	Less frequent dosing and simplified treatment	Labeling and clinical support
Pediatric liquid	Accurate low-volume dosing and better acceptability	Stability, preservative, and device validation
Vegetarian softgel	Appeals to dietary and religious preferences	Higher shell and process cost
Fast-dissolving tablet	Convenience for swallowing-limited patients	Taste and content uniformity
Self-emulsifying system	Potentially improved dispersion	Surfactant load and proof of benefit
Vitamin D plus calcium or vitamin K	Broad bone-health positioning	Combination evidence and competitive pricing
Renal-care formulation	Targets clinically defined patient populations	Active analogue competition and regulatory complexity
Low-oxidation premium product	Longer shelf life and quality positioning	Consumer ability to recognize technical differentiation

The most defensible commercial opportunity is a product that links excipient selection to a measurable patient or supply-chain benefit. Examples include a pediatric product with validated dose accuracy, a high-dose product with superior in-use stability, or a vegetarian softgel with equivalent shelf life to gelatin products.

How strong is the patent estate for vitamin D products?

The underlying vitamin D molecule has weak exclusivity because of its age and broad prior-art base. Conventional softgels, oil solutions, tablets, and supplements are difficult to protect with broad claims.

Patent strength improves when the product has:

• Narrow but commercially relevant composition claims.
• Comparative stability data.
• A defined manufacturing advantage.
• A validated delivery device.
• Clinical evidence supporting a new dosing method.
• Claims that cover both the active formulation and the commercial presentation.

Patent clearance should examine formulation patents, excipient combinations, delivery-device claims, manufacturing patents, and method-of-use claims across the United States, Europe, Japan, China, and other target markets. Supplement products may avoid some drug-patent issues but remain exposed to formulation, trademark, packaging, and manufacturing-process rights.

What generic launch risks exist for vitamin D?

Generic entry risk is high for conventional vitamin D products. A generic manufacturer can often compete through an ANDA or an equivalent national pathway when the reference product, dosage form, strength, and inactive-ingredient profile permit it.

Launch timing may be affected by:

• Active patent listings.
• Paragraph IV certifications.
• 30-month litigation stays under applicable U.S. rules.
• Formulation differences requiring additional data.
• Inactive-ingredient restrictions.
• Device or packaging requirements.
• Manufacturing-site readiness.
• State and channel-level substitution rules.

Paragraph IV risk is most relevant for approved prescription products with listed patents. It is less relevant to ordinary dietary supplements and mature products without active listed patents. A sponsor relying on formulation patents should expect challenges to validity, written description, enablement, obviousness, and infringement.

What licensing deals could create value?

Licensing opportunities are more likely to involve technology than the vitamin D molecule. Attractive assets include:

• Proprietary solubilization platforms.
• Pediatric dispensing systems.
• Stabilized premixes.
• Vegetarian capsule technologies.
• Controlled-release systems.
• Combination products with clinically supported dosing.
• Regional manufacturing and distribution rights.

A licensing agreement should define ownership of improvements, regulatory responsibility, supply obligations, stability specifications, minimum purchase commitments, and rights to use clinical or bioavailability data. For vitamin D, manufacturing economics and channel access may be more important than royalty rates because base-product prices are often low.

Key Takeaways

• Vitamin D is a mature small-molecule market with limited active-ingredient exclusivity.
• The main formulation challenges are lipophilicity, oxidation, photolysis, low-dose content uniformity, and patient acceptability.
• Oil-based softgels remain the lowest-risk commercial platform, but differentiation is limited.
• Pediatric liquids, vegetarian softgels, chewables, high-dose adherence products, and self-emulsifying systems offer stronger commercial positioning.
• Antioxidants, low-peroxide lipid vehicles, light protection, oxygen control, and validated premixes are central to product quality.
• Orange Book, Paragraph IV, and patent analysis must be performed at the individual approved-product level.
• Vitamin D has no conventional biosimilar risk; competition comes from generics, supplements, private-label products, and alternative analogues.
• The strongest patents claim measurable formulation or manufacturing advantages rather than conventional vitamin D compositions.
• Licensing value is concentrated in delivery technology, manufacturing capability, clinical positioning, and market access.

FAQs About Vitamin D Excipient Strategy

Which antioxidant is most commonly considered for vitamin D formulations?

Tocopherols, including alpha-tocopherol and mixed tocopherols, are commonly evaluated because vitamin D is oxidation-sensitive and frequently formulated in lipid vehicles. Selection depends on the oil, packaging, concentration, and degradation profile.

Is vitamin D better formulated in oil or water?

Oil is usually the simpler approach because vitamin D is highly lipophilic. Water-based emulsions can improve dosing flexibility and mouthfeel but require more extensive control of microbial, interfacial, and physical stability.

Can vitamin D be protected with a formulation patent?

Yes, but broad claims covering ordinary vitamin D capsules or tablets are difficult to defend. Stronger protection usually requires a specific composition, process, delivery system, or demonstrated stability or bioavailability advantage.

Are vitamin D supplements listed in the FDA Orange Book?

Generally, no. The Orange Book covers approved drug products and related patent and exclusivity information. Dietary supplements are regulated under a separate framework and are not treated as Orange Book-listed prescription products.

Which vitamin D product has the greatest unmet formulation need?

Pediatric oral liquids and products for patients with malabsorption or swallowing difficulty have the clearest formulation needs. The commercial opportunity depends on validated dose delivery, stability, tolerability, and regulatory positioning.

References

1. National Institutes of Health, Office of Dietary Supplements. (2022). Vitamin D fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase

4. U.S. Food and Drug Administration. (2022). FDA 101: Dietary supplements. https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements

5. U.S. Pharmacopeial Convention. (2024). USP-NF: Vitamin D-related monographs and general chapters. https://www.uspnf.com/

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files.